Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
- PMID: 40578380
- DOI: 10.1016/S1473-3099(25)00283-X
Unveiling the incidences and trends of alveolar echinococcosis in Europe: a systematic review from the KNOW-PATH project
Erratum in
-
Correction to Lancet Infect Dis 2025; published online June 24. https://doi.org/10.1016/S1473-3099(25)00283-X.Lancet Infect Dis. 2025 Sep;25(9):e497. doi: 10.1016/S1473-3099(25)00437-2. Epub 2025 Jul 11. Lancet Infect Dis. 2025. PMID: 40659024 No abstract available.
Abstract
Human alveolar echinococcosis is a notifiable parasitic infectious disease in most European countries; however, in practice, it is under-reported by national health systems. To fill this knowledge gap, data on the number, incidence, and trend of cases in Europe were extracted through a systematic review approach from both the scientific and grey literature, covering 1997-2023. This systematic review identified 4207 human alveolar echinococcosis cases from 28 of the 40 European countries investigated. Historically endemic Austria, France, Germany, and Switzerland accounted for 2864 (68·08%) of 4207 cases documented in Europe, and Lithuania, Poland, and Slovakia represented an additional 887 (21·08%) cases. Based on incidence rates and trends detected in this study, two main epicentres were seen in countries in the Alpine and the Baltic areas. The mean annual incidence from 1997 to 2023 throughout Europe was 0·063 cases per 100 000 people and in EU member states was 0·060 cases per 100 000 people. Data collected during this period suggest that alveolar echinococcosis is emerging in almost every country where this neglected parasitic infectious disease has been detected.
Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.
Conflict of interest statement
Declaration of interests FL declares funding for projects unrelated to this study from Hochschuljubilaumsfonds, Medizinisch-Wissenschaftlicher Fonds des Burgermeisters der Bundeshauptstadt Wien, Karl-Landsteiner-Gesellschaft, and Kooperation Entwicklung und Forschung; honoraria from Pfizer, Valneva, Shionogi, and Takeda; support for attending educational meetings from Diasorin; is a member of the board of the Austrian Society for Tropical Medicine, Parasitology, and Migration Medicine; and has stock or stock options in Eli Lilly. MSt declares consulting fees and support for attending meetings and travel from Gilead, paid to their institution; and participation on a data safety monitoring board or advisory board for MSD, Gilead, ViiV, and Moderna. PK declares grants or contracts from the German Research Foundation (Transmission ecology and risk factors for cystic echinococcosis in Sub-Saharan Africa). PC declares receiving travel expenses from Elanco Animal Health. All other authors declare no competing interests.
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous